What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?

MMF is likely to be noninferior to cyclophosphamide for the induction of remission in lupus nephritis. Early results suggest that MMF is equivalent to azathioprine for remission maintenance, although large randomized trial data are awaited to clarify the role. The optimal dosing strategy and duration of MMF treatment have not been established. The efficacy and safety of MMF in patients with severe renal impairment requires further investigation. Longer follow-up is required to fully assess the impact of MMF on renal survival and overall mortality.